Health
Freiburg immunologists decipher anti-cancer drug’s mode of operation – News-Medical.net
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University…
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients to investigate how CD20 organizes the nanostructures on the B cell membrane. If the protein is missing or Rituximab binds to it, the organization of the B cell surface…
-
General22 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News21 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
General24 hours agoBack-to-back rate cuts tipped when Reserve Bank meets
-
General22 hours agoLithium mine closure shines light on Ravensthorpe community’s resilience